Institution Directory

Clinical trials at University of Colorado Anschutz

Sites in Aurora, CO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:09 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1008

Shown on this page

Current sort

Live official records

Conditions: Obesity, Infertility, Hypogonadotropic Hypogonadotropism, Hyperinsulinemia
Interventions: Insulin, Intralipid, Dextrose, Heparin, GnRH, Hyperinsulinemic Euglycemic Clamp; Drug · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Heart Transplant Failure and Rejection
Interventions: The Prospera™ Test; Diagnostic Test
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more

Conditions: Mental Health, Hypertension, Diabetes
Interventions: Individual awareness and focused behavior change; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Advanced Melanoma
Interventions: Brenetafusp, Nivolumab, Nivolumab + Relatlimab; Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 37
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 30 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Tissue collection; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Head and Neck Cancer, Lip Cancer, Oral Cancer, Pharynx Cancer
Interventions: Metagenomic sequencing, Metabolic analysis; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years
Enrollment: 60 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
Interventions: Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Hypofractionated Radiation Therapy; Radiation · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 898 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2035
U.S. locations: 846
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more

Conditions: Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions: Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd); Biological
Lead sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma, Cholangiocarcinoma, Gallbladder Carcinoma
Interventions: tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Aurora, Colorado + 10 more

Conditions: Knee Arthritis, Osteoarthritis
Interventions: Eccentric resistance training; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 40 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Frostbite
Interventions: Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

About this University of Colorado Anschutz institution page

What this page lists: ClinicalTrials.gov records that list University of Colorado Anschutz in Aurora, CO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at University of Colorado Anschutz

Filter and sort this campus

Live official records

Reprometabolic Syndrome Mediates Subfertility in Obesity

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

Colorado Community Engagement Alliance

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

MicroRNA Markers in Head and Neck Cancers

Microbiome in Head and Neck Squamous Cell Carcinoma

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Knee Osteoarthritis Rehabilitation Through Rotational Inertia

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

About this University of Colorado Anschutz institution page